DELs enable the development of BRET probes for target engagement studies in cells
- Cell Chem Biol. 2023 Aug 17;30(8):987-998.e24. doi: 10.1016/j.chembiol.2023.06.019.
- 1. Promega Corporation, 2800 Woods Hollow Road, Fitchburg, WI 53711, USA.
- 2. WuXi AppTec Headquarters, 288 Fute Shong Road Waigaopqiao Free Trade Zone, Pudong District, Shanghai 200131, China.
- 3. Promega Biosciences Incorporated, 277 Granada Drive, San Luis Obispo, CA 93401, USA.
- 4. WuXi AppTec Headquarters, 288 Fute Shong Road Waigaopqiao Free Trade Zone, Pudong District, Shanghai 200131, China. Electronic address: [email protected].
- 5. Promega Corporation, 2800 Woods Hollow Road, Fitchburg, WI 53711, USA. Electronic address: [email protected].
DNA-encoded libraries (DELs) provide unmatched chemical diversity and starting points for novel drug modalities. Here, we describe a workflow that exploits the bifunctional attributes of DEL ligands as a platform to generate BRET probes for live cell target engagement studies. To establish proof of concept, we performed a DEL screen using Aurora Kinase A and successfully converted aurora DEL ligands as cell-active BRET probes. Aurora BRET probes enabled the validation and stratification of the chemical series identified from primary selection data. Furthermore, we have evaluated the effective repurposing of pre-existing DEL screen data to find suitable leads for BRET probe development. Our findings support the use of DEL workflows as an engine to create cell-active BRET probes independent of structure or compound SAR. The combination of DEL and BRET technology accelerates hit-to-lead studies in a live cell setting.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Cancer
-
Research Areas: Neurological Disease
-
Research Areas: Cancer